Insulin B-Chain

Overview

The insulin B-chain is a 30-amino acid polypeptide that, together with the 21-amino acid A-chain, constitutes the mature insulin molecule. First sequenced by Frederick Sanger in 1951, insulin was the first protein to have its complete amino acid sequence determined, a landmark achievement in biochemistry. The B-chain serves as the primary scaffold for receptor recognition and plays a critical role in maintaining the structural integrity of the insulin hexamer.

Structure and Disulfide Architecture

The B-chain contains a single intrachain disulfide bond between Cys7 and Cys72, and two interchain disulfide bonds linking it to the A-chain at positions A7-B7 and A20-B19. These covalent cross-links stabilize the folded conformation essential for biological activity. The B-chain helix spanning residues B9-B19 forms a hydrophobic surface that mediates initial contact with the insulin receptor. X-ray crystallography studies reveal that the B-chain C-terminus (B23-B30) exhibits conformational flexibility, adopting different orientations depending on the oligomeric state of insulin.

Biosynthesis and Processing

Insulin is synthesized as preproinsulin in pancreatic beta cells, where the signal peptide is cleaved in the endoplasmic reticulum to yield proinsulin. Proinsulin undergoes folding and disulfide bond formation before translocation to secretory granules. Prohormone convertases PC1/3 and PC2 cleave the C-peptide connecting the A- and B-chains, yielding the mature two-chain hormone. Zinc-dependent hexamer formation in secretory granules stabilizes proinsulin against degradation.

Receptor Binding and Signaling

The B-chain contributes significantly to insulin receptor binding. Residues B24-Phe, B25-Phe, and B26-Tyr are critical for high-affinity interaction with the insulin receptor’s alpha subunit. Mutations in the B-chain, such as the Chicago variant (Phe-B25-Leu), result in impaired receptor binding and clinical diabetes. Molecular dynamics simulations indicate that the B-chain undergoes conformational rearrangement upon receptor engagement, facilitating signal transduction through the beta subunit tyrosine kinase.

Clinical Significance

B-chain variants are associated with several forms of diabetes. The Wakayama mutation (Val-B3-Ala) reduces biological activity by approximately 50%. Understanding B-chain structure-function relationships has guided the design of insulin analogs, including lispro and aspart, which modify B-chain residues to alter pharmacokinetic properties. These engineered variants exploit the B-chain’s role in hexamer stability to achieve rapid-acting or long-acting therapeutic profiles.

References

Sanger F. The chemistry of insulin. Nature. 1952;169:441-443.
Dodson G, Steiner D. The role of assembly in insulin’s biosynthesis. Current Opinion in Structural Biology. 1998;8:189-194.
De Meyts P. The insulin receptor and its signaling network. Clinical Diabetes. 2004;22:189-194.